Home » Novartis and Alnylam to Collaborate on siRNA Therapy for Restoring Liver Function
Novartis and Alnylam to Collaborate on siRNA Therapy for Restoring Liver Function
Novartis and Alnylam Pharmaceuticals have teamed up to develop a small-interfering RNA (siRNA)-based drug to restore functional liver cells in patients suffering from end-stage liver disease.
In the three-year collaboration, Alnylam will develop and test possible siRNAs using target-specific assays provided by Novartis. After a lead candidate is identified, Novartis will handle all research and development.
End-stage liver disease is a progressive condition generally caused by cirrhosis, which is marked by the destruction of healthy liver tissue and critical liver function. The disease is responsible for over 1 million global deaths a year.
The companies did not disclose the financial terms of the agreement.
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May